Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Recent experience with immune checkpoint and kinase inhibitors shows significant and unexpected side-effects.

Lejeune FJ; Editors.

Melanoma Res. 2018 Dec;28(6):489-490. doi: 10.1097/CMR.0000000000000503. No abstract available.

PMID:
30371570
2.

The conquest of melanoma by immunotherapy.

Lejeune FJ.

Melanoma Res. 2015 Oct;25(5):373-5. doi: 10.1097/CMR.0000000000000178. No abstract available.

PMID:
26173006
3.

The debate on sentinel node biopsy in melanoma: any clue?

Matter M, Lejeune FJ.

Melanoma Res. 2012 Dec;22(6):413-4. doi: 10.1097/CMR.0b013e32835ae827. No abstract available.

PMID:
23111279
4.

Is surgical trauma prometastatic?

Lejeune FJ.

Anticancer Res. 2012 Mar;32(3):947-51. Review.

PMID:
22399615
5.

Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.

Cherix S, Speiser M, Matter M, Raffoul W, Liénard D, Theumann N, Mouhsine E, Mirimanoff RO, Leyvraz S, Lejeune FJ, Leyvraz PF.

J Surg Oncol. 2008 Sep 1;98(3):148-55. doi: 10.1002/jso.21081.

PMID:
18668638
6.

Sentinel lymph node involvement and a high Breslow index are independent factors of risk for early relapse of melanoma.

Willi JP, Matter M, Buchegger F, Antonescu C, Guggisberg D, Cerottini JP, Krischer J, Braun R, Marie Kurt A, Roche B, Lemoine R, Rimoldi D, Lejeune FJ, Liénard D, Bischof Delaloye A.

Nuklearmedizin. 2007;46(6):244-51.

7.

p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan.

Muret J, Yacoub M, Terrier P, Drusch F, Laplanche A, Gaudin C, Richon C, Le Péchoux C, Le Cesne A, Lejeune FJ, Tursz T, Fouret P, Bonvalot S, Chouaib S.

Ann Oncol. 2008 Apr;19(4):793-800. Epub 2007 Dec 6.

PMID:
18065405
8.

Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution.

Roulin D, Matter M, Bady P, Liénard D, Gugerli O, Boubaker A, Bron L, Lejeune FJ.

Eur J Surg Oncol. 2008 Jun;34(6):673-9. Epub 2007 Sep 6.

PMID:
17825518
9.

New approaches in metastatic melanoma: biological and molecular targeted therapies.

Lejeune FJ, Rimoldi D, Speiser D.

Expert Rev Anticancer Ther. 2007 May;7(5):701-13. Review.

PMID:
17492933
10.

Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.

Lejeune FJ, Eggermont AM.

J Clin Oncol. 2007 Apr 10;25(11):1449-50; author reply 1450-1. No abstract available.

PMID:
17416870
11.
12.

Recombinant human tumor necrosis factor: an efficient agent for cancer treatment.

Lejeune FJ, Rüegg C.

Bull Cancer. 2006 Aug;93(8):E90-100. Review.

13.
14.

Efficiency of recombinant human TNF in human cancer therapy.

Lejeune FJ, Liénard D, Matter M, Rüegg C.

Cancer Immun. 2006 Mar 22;6:6. Review.

15.

The new arms race against melanoma.

Lejeune FJ.

Melanoma Res. 2006 Feb;16(1):1-2. No abstract available.

PMID:
16432449
16.

Antiangiogenic peptides and proteins: from experimental tools to clinical drugs.

Rüegg C, Hasmim M, Lejeune FJ, Alghisi GC.

Biochim Biophys Acta. 2006 Apr;1765(2):155-77. Epub 2005 Oct 7. Review.

PMID:
16263219
17.

What is the impact of sentinel node biopsy in the management of cancer?

Lejeune FJ.

Ann Oncol. 2005 Aug;16(8):1217-8. Epub 2005 Jul 1. No abstract available.

PMID:
15994175
18.

Lack of BRAF mutations in uveal melanoma.

Rimoldi D, Salvi S, Liénard D, Lejeune FJ, Speiser D, Zografos L, Cerottini JC.

Cancer Res. 2003 Sep 15;63(18):5712-5.

19.

Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods.

Rimoldi D, Lemoine R, Kurt AM, Salvi S, Berset M, Matter M, Roche B, Cerottini JP, Guggisberg D, Krischer J, Braun R, Willi JP, Antonescu C, Slosman D, Lejeune FJ, Liénard D; Groupe Mélanome Lémanique.

Melanoma Res. 2003 Oct;13(5):511-20.

PMID:
14512793
20.

Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities.

Rossi CR, Lejeune FJ, Pontes L, Foletto M, De Salvo GL, Pilati PL, Mocellin S, Ribeiro M, Lopes M, Lise M.

Melanoma Res. 2003 Jun;13(3):293-7.

PMID:
12777985
21.

Modulation of cdk2, cyclin D1, p16INK4a, p21WAF and p27Kip1 expression in endothelial cells by TNF/IFN gamma.

Dormond O, Lejeune FJ, Ruegg C.

Anticancer Res. 2002 Nov-Dec;22(6A):3159-63.

PMID:
12530059
22.

Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response.

Christoforidis D, Chassot PG, Mosimann F, Lienard D, Brunstein F, Bejko D, Lejeune FJ, Chiolero R.

Arch Surg. 2003 Jan;138(1):17-25.

PMID:
12511144
23.

Isolated liver perfusion for non-resectable liver tumours: a review.

Christoforidis D, Martinet O, Lejeune FJ, Mosimann F.

Eur J Surg Oncol. 2002 Dec;28(8):875-90. Review.

PMID:
12477481
24.
25.

The impact of surgery on the course of melanoma.

Lejeune FJ.

Recent Results Cancer Res. 2002;160:151-7.

PMID:
12079209
26.

Isolated limb perfusion: the European experience.

Lejeune FJ, Kroon BB, Di Filippo F, Hoekstra HJ, Santinami M, Liénard D, Eggermont AM.

Surg Oncol Clin N Am. 2001 Oct;10(4):821-32, ix. Review.

PMID:
11641093
27.

TNF is here to stay--revisited.

ten Hagen TL, Eggermont AM, Lejeune FJ.

Trends Immunol. 2001 Mar;22(3):127-9. No abstract available.

PMID:
11334026
28.

Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.

Lejeune FJ, Pujol N, Liénard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot PG, Chiolero R, Bischof-Delaloye A, Leyvraz S, Mirimanoff RO, Bejkos D, Leyvraz PF.

Eur J Surg Oncol. 2000 Nov;26(7):669-78.

PMID:
11078614
29.

High tPA-expression in primary melanoma of the limb correlates with good prognosis.

Ferrier CM, Suciu S, van Geloof WL, Straatman H, Eggermont AM, Koops HS, Kroon BB, Lejeune FJ, Kleeberg UR, van Muijen GN, Ruiter DJ.

Br J Cancer. 2000 Nov;83(10):1351-9.

30.

Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.

Liénard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, Schmitz P, Clarke J, Steinmann G, Rosenkaimer F, Lejeune FJ.

Melanoma Res. 1999 Oct;9(5):491-502.

PMID:
10596916
31.

Complete remission of advanced cutaneous leiomyosarcoma following isolated limb perfusion with high-dose tumour necrosis factor-alpha and melphalan.

Häffner AC, Zepter K, Fritz T, Dummer R, Lejeune FJ, Burg G.

Br J Dermatol. 1999 Nov;141(5):935-6. No abstract available.

PMID:
10583188
32.

Sunscreen use and duration of sun exposure: a double-blind, randomized trial.

Autier P, Doré JF, Négrier S, Liénard D, Panizzon R, Lejeune FJ, Guggisberg D, Eggermont AM.

J Natl Cancer Inst. 1999 Aug 4;91(15):1304-9.

PMID:
10433619
33.
34.

[Melanoma update].

Lejeune FJ.

Bull Cancer. 1999 Jan;86(1):47-51. Review. French. No abstract available.

35.

Clinical applications of TNF-alpha in cancer.

Lejeune FJ, Rüegg C, Liénard D.

Curr Opin Immunol. 1998 Oct;10(5):573-80. Review.

PMID:
9794839
36.

Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.

Schraffordt Koops H, Eggermont AM, Liènard D, Kroon BB, Hoekstra HJ, van Geel AN, Nieweg OE, Lejeune FJ.

Radiother Oncol. 1998 Jul;48(1):1-4. Review.

PMID:
9756165
39.

Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas.

Schraffordt Koops H, Eggermont AM, Liénard D, Kroon BB, Hoekstra HJ, Van Geel AN, Nieweg OE, Lejeune FJ.

Semin Surg Oncol. 1998 Apr-May;14(3):210-4. Review.

PMID:
9548603
40.

Isolated limb perfusion in primary and recurrent melanoma: indications and results.

Liénard D, Eggermont AM, Kroon BB, Schraffordt Koops H, Lejeune FJ.

Semin Surg Oncol. 1998 Apr-May;14(3):202-9.

PMID:
9548602
41.

Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma.

Rüegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ.

Nat Med. 1998 Apr;4(4):408-14.

PMID:
9546785
42.

Principles and guidelines for surgeons: management of cutaneous malignant melanoma. European Society of Surgical Oncology Brussels.

Kroon BB, Nieweg OE, Hoekstra HJ, Lejeune FJ.

Eur J Surg Oncol. 1997 Dec;23(6):550-8. Review.

PMID:
9484929
43.

The management of malignant melanoma revisited.

Lejeune FJ.

Acta Chir Belg. 1997 Oct;97(5):209-14. Review. No abstract available.

PMID:
9394960
44.

Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.

Eggermont AM, Schraffordt Koops H, Klausner JM, Liénard D, Kroon BB, Schlag PM, Ben-Ari G, Lejeune FJ.

Semin Oncol. 1997 Oct;24(5):547-55.

PMID:
9344321
45.

Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.

Furrer M, Altermatt HJ, Ris HB, Althaus U, Rüegg C, Liénard D, Lejeune FJ.

Melanoma Res. 1997 Aug;7 Suppl 2:S43-9.

PMID:
9578416
46.

Cell differentiation and cell-cycle alterations by tyrosine kinase inhibitors in human melanoma cells.

Hartmann RR, Rimoldi D, Lejeune FJ, Carrel S.

Melanoma Res. 1997 Aug;7 Suppl 2:S27-33.

PMID:
9578414
47.

Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas.

Eggermont AM, Schraffordt Koops H, Klausner JM, Schlag PM, Kroon BB, Ben-Ari G, Lejeune FJ.

Cancer Treat Res. 1997;91:189-203. No abstract available.

PMID:
9286497
48.

Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.

Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Liénard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ.

Ann Surg. 1996 Dec;224(6):756-64; discussion 764-5.

49.

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.

Eggermont AM, Schraffordt Koops H, Liénard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ.

J Clin Oncol. 1996 Oct;14(10):2653-65.

PMID:
8874324
50.

TNF alpha: shock-free cancer remission.

Lejeune FJ, Liénard D.

Nat Biotechnol. 1996 Jun;14(6):706, 708. No abstract available.

PMID:
9630973

Supplemental Content

Loading ...
Support Center